CM Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

CM Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-250,000	Closed	-$553K	–	74
2023 Q2	$553K	Sell	250,000 -200,000	-44%	-$415K	0.54%	51
2023 Q1	$1.14M	Buy	450,000 +105,000	+30%	+$207K	1.36%	30
2022 Q4	$645K	Sell	345,000 -55,000	-14%	-$137K	0.77%	45
2022 Q3	$1.03M	Buy	400,000 +50,000	+14%	+$124K	1.15%	31
2022 Q2	$676K	Hold	350,000	–	–	0.72%	46
2022 Q1	$1.04M	Buy	350,000 +50,000	+17%	+$188K	0.87%	40
2021 Q4	$1.35M	Buy	300,000 +100,000	+50%	+$474K	1.02%	31
2021 Q3	$972K	Buy	200,000 +25,000	+14%	+$138K	0.72%	50
2021 Q2	$1.19M	Buy	175,000 +25,000	+17%	+$202K	0.86%	45
2021 Q1	$1.06M	Buy	150,000 +115,000	+329%	+$828K	0.79%	52
2020 Q4	$219K	Buy	+35,000	New	+$206K	0.2%	74

CM Management's PRTK Position: Q3 2023 in Review

CM Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2023, closing a stake of 250,000 shares — an estimated $553K sold.

CM Management first reported a position in PRTK in Q4 2020 and held it in 11 quarters. The position peaked at $1.35M in Q4 2021. 0 funds tracked by Wall St. Rank hold PRTK as of Q3 2023.

CM Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
CM Management sold 250,000 Paratek Pharmaceuticals, Inc. shares in Q3 2023, an estimated $553K.
CM Management first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2020 and held it in 11 quarters.
CM Management's Paratek Pharmaceuticals, Inc. position peaked at $1.35M in Q4 2021.
0 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2023.

Based on CM Management's 13F filing for Q3 2023, filed 7 Nov 2023.